Company / Revenue
Dianthus Therapeutics, Inc. /DE/ Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$2.0M
FY2025
5-year range
$2.0M / $2.8M
FY2021-FY2025
Trend
-28.0%
vs FY2024
Sector context
#144 of 155
Health Care
What the data says
Among 155 Health Care companies, Dianthus Therapeutics, Inc. /DE/ is in the bottom 7% for revenue. Declined from $3M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2025.
Declined from $3M to $2M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 155This company $2.0M Sector average $4.5B
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2025, revenue decreased 28.0% year-over-year.
- Ranks #144 out of 155 companies in the Health Care sector.
- Peak revenue was recorded in FY2024.
- Lowest revenue in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0M | -28.0% |
| FY2024 | $2.8M | +0.0% |
| FY2023 | $2.8M | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $0 | - |
| FY2018 | $0 | - |
| FY2017 | $0 | - |
| FY2016 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026